No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers

Canadian Journal of Cardiology

Volumn 29, Issue 5, 2013, Pages 586-591

  Gilbert, Cameron J ^a   Gomes, Tara ^b,c,d   Mamdani, Muhammad M ^b,c,d,e   Hellings, Chelsea ^b   Yao, Zhan ^b   Garg, Amit X ^b,f   Wald, Ron ^d,g   Harel, Ziv ^d,g   Juurlink, David N ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMMUNITY LIVING; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HOSPITALIZATION; HUMANS; HYPERKALEMIA; LOGISTIC MODELS; MALE; ONTARIO; RENIN; RISK FACTORS; STROKE;

EID: 84876796876     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.02.015     Document Type: Article

References (35)

1. Yusuf S., Teo K.K., Pogue J., the ONTARGET investigators, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. NEJM 2008, 358:1547-1559.
2. Heart Outcomes Prevention Evaluation Study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
3. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987, 316:1429-1435.
4. Dickstein K., Kjekshus J., the OPTIMAAL Steering Committe Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: optimaal randomised trial. Lancet 2002, 360:752-760.
5. Rahuel J., Rasetti V., Maibaum J., et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chemistry & Biology 2000, 7:493-504.
6. Brown M.J., McInnes G.T., Papst C.C., Zhang J., MacDonald T.M. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011, 377:312-320.
7. Oparil S., Yarrows S., Patel S., Fang H., Zhang J., Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007, 370:221-229.
8. Oh B.H., Mitchell J., Herron J.R., Chung J., Khan M., Keefe D.L. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007, 49:1157-1163.
9. Musini V.M., Fortin P.M., Bassett K., Wright J.M. Blood pressure lowering efficacy of renin inhibitors for primary hypertension (review). Cochrane Database Syst Rev 2008, 4:CD007066.
10. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004, 351:543-551.
11. Venzin R.M., Cohen C.D., Maggiorini M., Wüthrich R.P. Aliskiren-associated acute renal failure with hyperkalemia. Clin Nephrol 2009, 71:326-328.
12. Harel Z., Gilbert C., Wald R., et al. The effect of combination therapy with aliskiren and blockers of the renin angiotensin system on hyperkalemia and acute kidney injury: a systematic review and meta-analyses. BMJ 2012, 344:1-13.
13. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. NEJM 2012, 367:2204-2213.
14. Schmidt Firm, LLP. Tekamlo lawsuit. Available at:. Accessed April 29, 2012. http://www.schmidtlaw.com/tekamlo-lawsuit/.
15. Levy A.R., O'Brien B.J., Sellors C., Grootendorst P., Willison D. Coding accuracy of administrative drug claims in the Ontario drug benefit database. Can J Clin Pharmacol 2003, 10:67-71.
16. Hux J.E., Ivis F., Flintoft V., Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002, 25:512-516.
17. Juurlink D.N., Mamdani M., Kopp A., Laupacis A., Redelmeier D.A. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003, 289:1652-1658.
18. Park-Wyllie L.Y., Juurlink D.N., Kopp A., et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006, 354:1352-1361.
19. Lipscombe L.L., Gomes T., Lévesque L.E., Hux J.E., Juurlink D.N., Alter D.A. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007, 298:2634-2643.
20. Zhao Y.Y., Weir M.A., Manno M., et al. New fibrate use and acute renal outcomes in elderly adults. Ann Intern Med 2012, 156:560-569.
21. Juurlink D.N., Gomes T., Ko D.T., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180:713-718.
22. Lubin J.H., Gail M.H. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984, 40:63-75.
23. Austin P.C., Grootendorst P., Anderson G.M. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007, 26:734-753.
24. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
25. Hackam D.G., Thain L.M.F., Abassakoor A., McKenzie F.N., Spence J.D. Trapped renal arteries: functional renal artery stenosis due to occlusion of the aorta in the arch and below the kidneys. Can J Cardiol 2001, 17:587-592.
26. Waikar S.S., Wald R., Chertow G.M., et al. Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. J Am Soc Nephrol 2006, 17:1688-1694.
27. Kokotailo R.A., Hill M.D. Coding of stroke and stroke risk factors using International Classification of Diseases, Revisions 9 and 10. Stroke 2005, 36:1776-1781.
28. So L., Evans D., Quan H. ICD-10 coding algorithms for defining comorbidities of acute myocardial infarction. BMC Health Serv Res 2006, 6:1-9.
29. Antoniou T., Gomes T., Mamdani M.M., et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ 2011, 343:d5228.
30. Imamura T., Matsuura Y., Nagoshi T., et al. Hyperkalemia induced by the calcium channel blocker, benidipine. Intern Med 2003, 42:503-506.
31. Johnson E.I., McDougall J.G., Coghlan J.P., Denton D.A., Scoggins B.A., Wright R.D. Potassium stimulation of aldosterone secretion in vivo is reversed by nisoldipine, a calcium transport antagonist. Endocrinology 1984, 114:1466-1468.
32. Makani H., Bangalore S., Desouza K.A., et al. Efficacy and safety of dual blockade of the renin-angiotensin system: a meta-analysis of randomized trials. BMJ 2013, 246:f360.
33. Pfeffer M.A., Swedberg K., Granger C.B., CHARM investigators, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
34. Gheorghiade M., Albaghdadi M., Zannad F., et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011, 13:100-106.
35. Krum H., Massie B., Abraham W.T., et al. Direct renin inhibition in addition to or as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011, 13:107-114.